Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling

被引:0
作者
Kelli Swan
Kali Chatham Dougherty
Sara Wienke Myers
机构
[1] PerkinElmer Genomics,
[2] Myriad Genetics,undefined
[3] Guardant Health,undefined
来源
Current Genetic Medicine Reports | 2020年 / 8卷
关键词
Targeted therapy; Germline; Somatic; PARP inhibitor; Immunotherapy; Genetic counseling;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:109 / 119
页数:10
相关论文
共 468 条
[1]  
Gutierrez M(2017)Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities Clin Lung Cancer 18 651-659
[2]  
Choi K(2019)Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients Clin Oncol 37 1305-1315
[3]  
Lanman R(2019)Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer JAMA Oncol 5 173-180
[4]  
Kurian A(2017)Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer Onco Targets Ther 10 2539-2551
[5]  
Ward K(2017)PARP inhibitors: the first synthetic lethal targeted therapy Science. 355 1152-1158
[6]  
Howlander N(2017)Olaparib for metatatic breast cancer in patients with a germline BRCA mutation N Engl J Med 377 523-533
[7]  
Aggarwal C(2018)Talazoparib in patients with advanced breast cancer and germline BRCA mutation N Engl J Med 279 753-763
[8]  
Thompson C(2018)Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer N Engl J Med 379 2495-2505
[9]  
Black T(2019)Maintenance olaparib for germline N Engl J Med 381 317-327
[10]  
Hollis RL(2019)-mutated metastatic pancreatic cancer Cancer Disc 9 210-219